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Abstract
Sepsis is aggravated by an inappropriate immune response to invading microorganisms, which occasionally leads to
multiple organ failure. Several lines of evidence suggest that the ventricular myocardium is depressed during sepsis with
features of diastolic dysfunction. Potential candidates responsible for septic cardiomyopathy include pathogen-associated
molecular patterns (PAMPs), cytokines, and nitric oxide. Extracellular histones and high-mobility group box 1 that function
as endogenous damage-associated molecular patterns (DAMPs) also contribute to the myocardial dysfunction associated
with sepsis. If untreated, persistent shock causes cellular injury and the liberation of further DAMPs. Like PAMPs, DAMPs
have the potential to activate inflammation, creating a vicious circle. Early infection control with adequate antibiotic care
is important during septic shock to decrease PAMPs arising from invasive microorganisms. Early aggressive fluid
resuscitation as well as the administration of vasopressors and inotropes is also important to reduce DAMPs generated by
damaged cells although excessive volume loading, and prolonged administration of catecholamines might be harmful.
This review delineates some features of septic myocardial dysfunction, assesses its most common underlying
mechanisms, and briefly outlines current therapeutic strategies and potential future approaches.
Keywords: Damage-associated molecular patterns, Immune system, Infection, Septic shock, Systemic inflammatory
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Introduction
Sepsis has been defined by consensus as a systemic
inflammatory response syndrome (SIRS) to infection
[1, 2]. It is generally viewed as being aggravated by
an inappropriate immune response, and it occasionally
leads to multiple organ failure and shock. The pathophysi-
ology of septic shock is thought to involve complex inter-
actions between pathogens and a host immune system.
Recent advances in the molecular biology of sepsis have
shown that the host immune system recognizes infection
through recognition of pathogen-associated molecular
patterns (PAMPs), such as lipopolysaccharide (LPS),
lipoteichoic acid, flagellin and DNA in bacteria, man-
nan in fungi, and single- or double-stranded RNA in vi-
ruses. These mediators bind to pattern-recognition
receptors (PRRs), such as toll-like receptors (TLRs) that
are expressed on the surface of host cells. These PRRs
are essential for initiating host immune defenses against
invading pathogens and mediating PAMP recognition.
They also serve as receptors for endogenous danger sig-
nals by identifying various damage-associated molecu-
lar patterns (DAMPs) as potent activators of the innate
immune system [3–5]. The proinflammatory response
induced by infection is normally balanced by anti-
inflammatory cytokines. However, the normally effect-
ive inflammatory response to infection becomes sys-
temically dysregulated during sepsis due to significantly
imbalanced cytokine responses referred to as a cytokine
storm. Ten TLRs have been identified in the human
genome [6], and interactions between TLRs and PAMPs
activate intracellular signal-transduction pathways that
lead to the nuclear translocation of nuclear factor-κB
(NF-κB) and the increased transcription of inflamma-
tory mediators [7]. Among these, proinflammatory cy-
tokines such as tumor necrosis factor-alpha (TNF-α)
and interleukin-1-beta (IL-1β), chemokines, and lipid
mediators play major roles in the inflammatory process
[8]. The production of excess antimicrobial products
and inflammatory mediators elicits the generation of re-
active oxygen and nitrogen species, superoxide anion
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−), and nitric oxide (NO), causing adjacent tissue dam-
age and an amplified inflammatory reaction [9, 10]. The
DAMPs released during tissue damage include heat-shock
proteins, high-mobility group box 1 (HMGB1), histones,
and oxidized lipoproteins. Other cytosolic constituents
such as adenosine triphosphate (ATP) and mitochondrial
products, including mitochondrial DNA (mtDNA), can
also contribute to the activation of innate immunity that
initiates SIRS and a sepsis-like state. Excessive production
of DAMPs can activate inflammation, create a vicious cir-
cle, and finally facilitate cardiac dysfunction, multiple
organ failure (MOF), and death. This review describes
some important features of septic myocardial dysfunction,
assesses the key underlying mechanisms of cardiac dys-
function in sepsis, and briefly outlines current therapeutic
strategies and potential future approaches.
Review
Pathophysiology of septic shock and secondary
myocardial dysfunction
Septic distributive shock is a circulatory maldistribution
associated with peripheral vasodilation, as well as arterial
and capillary shunting. However, the pathophysiology of
septic shock comprises both warm (hyperdynamic) and
cold (hypodynamic) types. The early phase of septic
shock is called hyperdynamic, or warm shock, that is
characterized by high cardiac output, low peripheral vas-
cular resistance, and warm extremities (Fig. 1(a–c)). The
late phase comprises concomitant hypotension followed
by hypodynamic, or cold shock, with low cardiac output,
poor peripheral perfusion, cool extremities (Fig. 1(d)),
and finally, death [11–13]. Inadequate resuscitation, rela-
tive hypovolemia, and an increased afterload were ini-
tially thought to be the hemodynamic profile of patients
with hypodynamic shock [14, 15]. Adequate volume re-
suscitation and the profoundly reduced systemic vascu-
lar resistance typically encountered in patients with
sepsis lead to a normal or elevated cardiac index [16].
However, despite increased cardiac output and a normal
stroke volume, myocardial dysfunction is significant in
patients with septic shock. Notably, ejection fraction
(EF) is lower and end-diastolic volume (EDV) is higher
in survivors, compared to non-survivors of shock. This
suggests that ventricular dilation might be a compensa-
tory mechanism to maintain adequate cardiac output


















Fig. 1 Pathophysiology of septic shock and secondary myocardial dysfunction. (a) In the normal condition, cardiac output is adequate to meet
the oxygen demand in peripheral tissues. (b) At the very early phase of sepsis, LV ejection fraction (EF) is not impaired (typically LVEF >55 %), but
stroke volume (SV) is low because of insufficient cardiac preload due to a high vascular permeability and vasodilation. The compensatory increase
in heart rate (HR) is often insufficient to maintain adequate cardiac output. (c) After fluid loading, SV can be recovered especially in the case of
survivors while LVEF is temporarily decreased (typically <45 %) in part due to high LVEDV. This indicates that low LVEF may represent preload
optimization and good adaptation. (d) During the later phase of sepsis, non-survivors are given more fluid than survivors but, nevertheless, have
lower LVEDV suggesting a persistent vascular hyperpermeability and preload deficiency. In these cases, LVEF can be retained in part due to low
LVEDV and/or ongoing harmful adrenergic over-stimulation
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study of 90 patients with septic shock identified global
left ventricular (LV) hypokinesia in 51 % of patients dur-
ing the first 48 h of treatment [18]. They also found that
patients who died had a significantly stop higher left
ventricular ejection fraction (LVEF) and a significantly
lower left ventricular end-diastolic volume (LVEDV)
than those who recovered; the latter were insensitive to
volume loading (Fig. 1(c, d)). Other studies of septic
shock lasting 48 h have found that 24 to 44 % of patients
had systolic LV dysfunction and a further 44 % had
echocardiographic features of diastolic dysfunction
[19–21]. These EF abnormalities are reversible, with
full recovery of cardiac function at 7 to 10 days after the
onset of sepsis. However, more fluids were administered
during the first 24 h of intensive care, and the overall mor-
tality rate was higher among patients with myocardial de-
pression than in those without myocardial dysfunction
[21]. Importantly, cardiovascular dysfunction in sepsis is
associated with a significantly increased mortality rate of
70–90 % compared with 20 % among patients with sepsis
that is not accompanied by cardiovascular impairment
[22]. Myocardial edema due to inflammation-induced vas-
cular leakage might also influence cardiac compliance and
function [23, 24]. In addition, ventricular function is influ-
enced by changes in afterload. Pulmonary hypertension
will worsen right-heart function [25], whereas right-heart
dilation will impair left-heart function [26]. Endothelial
cells producing vasoactive molecules that regulate periph-
eral vascular resistance are impaired during septic
shock, and thus, endothelial dysfunction plays a cru-
cial role in its pathophysiology [27]. This is because
impaired endothelium-derived NO release could alter the
physiological regulation of blood flow distribution via cor-
onary vasospasm combined with an increase in peripheral
vascular resistance and the associated elevation of cardiac
workload and myocardial oxygen demand.
In conclusion, despite high LVEF (typically >55 %),
stroke volume at the very early phase of sepsis is low
because of insufficient cardiac preload due to a high
vascular permeability and vasodilation (Fig. 1(b)). The
compensatory tachycardia is often insufficient to maintain
adequate cardiac output during this very early phase of
sepsis, as demonstrated by elevated lactate levels.
After fluid loading, LVEF was markedly decreased
(typically <45 %) in all patients during the first 3 days
of hemodynamic support (Fig. 1(c)). However, LV systolic
dysfunction is common in septic patients and potentially
reversible in survivors. During the later phase of sepsis,
non-survivors were given more fluid than survivors but,
nevertheless, had lower LVEDV suggesting a persistent
preload deficiency (Fig. 1(d)). Some studies reported more
cardiac depression in sepsis survivors compared to
non-survivors [17, 18]. How can such conflicting results
be explained? In very severe septic patients, the presence
of profound myocardial depression defined by a low LVEF
may represent preload optimization and good adaptation,
while a normal LVEF could be caused by persistent
preload deficiency and/or ongoing harmful adrenergic
over-stimulation (Fig. 1(c, d)).
Global ischemia and myocardial dysfunction in sepsis
Early sepsis and septic shock are characterized by circu-
latory abnormalities that are usually related to intravas-
cular volume depletion and vasodilation. This potentially
causes an oxygen supply–demand imbalance in various
organ beds [28], and cardiac performance is likely to be
reduced in insufficiently resuscitated animal models
[29–31]. Therefore, earlier theories suggested that global
myocardial ischemia might be responsible for myocardial
dysfunction in sepsis. However, Cunnion et al. found in
a study of coronary sinus catheterization that coronary
flow was the same or greater in patients with septic shock
compared with normal individuals. Although all of these
findings reflect important changes in coronary flow and
myocardial metabolism, and mirror the effects in the per-
ipheral circulation during sepsis, evidence does not support
the notion that global ischemia is an underlying cause of
myocardial dysfunction in sepsis. Macrocirculatory coron-
ary blood flow is increased in patients with established sep-
tic shock [32, 33], but cardiac microcirculation undergoes
major changes during sepsis with endothelial disruption
and blood flow maldistribution [34]. Heterogeneous car-
diac microvascular blood flow, swollen endothelial cells,
and non-occlusive intravascular fibrin depositions have
been found in the hearts of dogs with endotoxemia
[35, 36]. In addition, circulating neutrophils migrate into
the interstitium [37]. These findings indicated that
changes in the distribution of flow were localized to areas
of ischemia and that this could explain the occasional ap-
pearance of elevated troponin levels associated with the
severity of cardiac dysfunction [38]. However, Hotchkiss
et al. [39] did not find cellular hypoxia in the hearts of rats
with sepsis using the marker [18F]fluoromisonidazole.
The current belief is that increases in plasma troponin are
due to increased membrane permeability induced by myo-
cardial cytokines, although this remains a matter of de-
bate. As in the peripheral circulation, these changes could
be attributed to disrupted flow autoregulation or oxygen
utilization [40, 41]. Several magnetic resonance studies
have identified normal levels of high-energy phosphate in
the myocardium of animal models of sepsis [42, 43]. In
addition, myocardial dysfunction in sepsis might reflect a
hibernating myocardium [44]. The adequate O2 supply in
sepsis suggests that myocardial depression is not related
to tissue hypoperfusion but rather to circulating depres-
sant factors or other mechanisms. Endothelial damage
and induction of the coagulatory system also contribute to
the pathophysiology of septic cardiomyopathy.
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Direct myocardial depression in sepsis
A major mechanism of direct cardiac depression in
sepsis is the attenuation of the adrenergic response at
the cardiomyocyte level due to down-regulation of β-
adrenergic receptors and depression of post-receptor
signaling pathways. These changes seem to be medi-
ated by many substances, such as cytokines and nitric
oxide. Another mechanism of direct cardiac depression in
sepsis is cardiomyocyte injury or death, which can be
induced by toxins, complements, DAMPs, and as-yet-
unidentified myocardial depressants (Fig. 2).
Myocardial depressants
Numerous bacterial toxins as well as primary, secondary,
and final mediators are usually involved in the pathogen-
esis of systemic inflammation. A myocardial depressant
factor (MDF) was discovered in an experimental animal
model of hemorrhagic shock during 1947 [45]. The
MDF determined in the blood of dogs during induced
endotoxic shock seemed to be an 800–1000 dalton peptide
that originated in the pancreas [46]. Parrillo et al. [47]
quantitatively linked the clinical degree of septic myocar-
dial dysfunction with the effect of serum from septic pa-
tients on rat cardiac myocytes during 1985; clinical severity
correlated with a decrease in the extent and velocity of
myocyte shortening. These effects were notably absent
when serum was applied that had been sourced from
patients who were convalescing from sepsis or who
were critically ill but without sepsis. Several MDFs have
been identified, although the chemical composition of
others remains unknown [48–50]. Nevertheless, the
combination of TNF-α and IL-1β is extremely cardiode-
pressive [51]. Administering recombinant TNF-α to ani-
mal models elicits fever, lactic acidosis, hemodynamic
changes, and even death. Many studies of anti-TNF-α
antibodies in humans and other animals have found a
rapid improvement in cardiovascular parameters but no
decrease in mortality [52, 53]. Cytokines (TNF-α and
IL-1β) might play key roles in the early decrease in
contractility, but they cannot explain the prolonged myo-
cardial dysfunction in sepsis because the effect of TNF-α
is maximal between 8 and 48 h after administration [54].
Both TNF-α and IL-1β induce the release of additional
factors (such as NO) that in turn alter myocardial function
[55, 56]. A constellation of factors rather than any individ-
ual factor might influence the onset of sepsis-induced
myocardial dysfunction through the release, activation, or





















Fig. 2 Direct myocardial depression in sepsis. A major mechanism of direct cardiac depression in sepsis is cardiomyocyte hyporesponsiveness
due to down-regulation of β-adrenergic receptors and depression of post-receptor signaling pathways. These changes seem to be mediated by
many substances, including cytokines and nitric oxide. Another mechanism of direct cardiac depression is cardiomyocyte injury or death, which
can be induced by toxins, complements, damage-associated molecular patterns (DAMPs), neutrophil extracellular traps (NETs), and as-yet-unidentified
myocardial depressant factors (MDFs). MOF multiple organ failure, PAMPs pathogen-associated molecular patterns, PRRs pattern recognition receptors
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Cytokines and nitric oxide
Both TNF-α and IL-1β are primary players in the hier-
archy of proinflammatory mediator cascades [57], whereas
nitric oxide (NO) [58] and oxygen-free radicals [59] are
secondary effectors in the setting of SIRS cardiodepres-
sion. Sepsis leads to the expression of inducible NO syn-
thase (iNOS) in the myocardium [60, 61] followed by high
levels of NO production. This consequently contributes to
myocardial dysfunction and increases total levels of sarco-
plasmic reticulum Ca2+ and myofilament sensitivity to
Ca2+ [62], partly through the generation of cytotoxic
peroxynitrite from a diffusion-controlled reaction between
NO and another free radical, superoxide. Sepsis-induced
myocardial depression can be prevented in vitro by
administering nonspecific NOS inhibitors, for example,
inhibitors of guanylate cyclase such as N-methyl-L-argin-
ine and methylene blue [63]. Infusing methylene blue into
patients with sepsis strikingly improves mean arterial pres-
sure, stroke volume, and left ventricular stroke work and
decreases the requirement for inotropic support. Yet, the
outcomes remain unaltered [64]. Conflicting results from
studies of selective and nonselective iNOS inhibition indi-
cate that constitutive NOS isoforms, such as neuronal
(nNOS) and endothelial (eNOS), have potential roles in
regulating cardiomyocyte homeostasis and function.
These constitutive NOS isoforms may play an important
role in the very early phase of myocardial depression.
Myocardial eNOS in the sarcolemmal membrane pro-
duces NO that modifies L-calcium channels to inhibit cal-
cium entry and induces myofibril relaxation, which might
play an important protective role against sepsis-induced
myocardial dysfunction [65, 66]. Neuronal NOS is a com-
ponent of the central and peripheral nervous systems, and
it is constitutively expressed in cardiac myocytes. Several
studies have shown that nNOS can regulate the β-
adrenergic receptor pathway [67]. A functional NOS that
was recently identified in red blood cells (rbcNOS) regu-
lates the deformability of erythrocyte membranes and in-
hibits platelet activation in sepsis [68]. Since many NOS
isoforms have various modulating interactions and dose-
dependent NO effects and given the precise balance
among NO, superoxide, and thus peroxynitrite generated
in subcellular compartments, further advances in under-
standing the complexity of NO biology and its derived re-
active nitrogen species offer the promise of new, more
specific, and effective therapeutic targets.
Mitochondrial dysfunction
Since the heart is rich in mitochondria that are not only
involved in energy provision but also in intracellular cal-
cium regulation, the degree of mitochondrial dysfunction
is tightly linked to sepsis-induced cardiac dysfunction and
prognosis [69–71]. The activities of complexes I and II of
the mitochondrial respiratory chain are diminished in
hearts from animals with sepsis [72, 73], and this might be
due to the detrimental effects of sepsis mediators such as
NO [74], TNF-α, IL-1β [75], and others. Mitochondrial
permeability transition pores might also play a role in the
development of mitochondrial dysfunction [76]. Reactive
oxygen species (ROS) such as superoxide and NO sup-
press mitochondrial function during sepsis. This ultim-
ately causes an increase in mitochondrial mass due to
internal edema within mitochondria that is often associ-
ated with their dysfunction. One theory suggests that
sepsis-induced myocardial dysfunction could represent a
protective adaptation to reduced energy consumption dur-
ing a state of low levels of ATP produced by dysfunctional
mitochondria. This is similar to the phenomenon of the
hibernating myocardium during ischemia. Recent studies
have found that mitochondria generate a significant
amount of DAMPs [77], including mtROS, mtDNA frag-
ments, ATP [78, 79], and cytochrome C [80, 81]. These
molecules are released from fragmented mitochondria
into the circulatory system during cell death and organ
damage, initiating inflammatory responses through multi-
factorial pathways.
DAMPs: histones and HMGB1
Extracellular histones function as endogenous DAMPs
that might interact with TLR2 and TLR4 on various cell
types, including cardiomyocytes to reduce mitochondrial
membrane potential and ATP levels. These activities cause
cell damage, the dysfunction of organs including the heart,
and lethality [82–84]. Extracellular histones appear to
arise in a complement (C5a)-dependent fashion related to
neutrophil activation that results in neutrophil extracellu-
lar traps (NETs) [85]. Exposing cardiomyocytes to histones
in vitro results in obvious [Ca2+]i elevation in cardiomyo-
cytes and a loss of homeostasis in the redox system and in
[Ca2+]i, as well as defects in mitochondrial function due to
increased membrane permeability [86]. We did not detect
histone H3 in plasma from healthy volunteers but found
significant levels in patients with sepsis and disseminated
intravascular coagulation (DIC), especially in those who
did not survive [87]. Alhamdi et al. [88] showed similar
findings, and they also discovered that circulating histone
concentrations closely correlate with elevated levels of car-
diac troponin T (cTnT) in patients with sepsis, which
probably contributes to septic cardiac events and mortal-
ity. They concluded that circulating histones are novel and
important mediators of septic cardiomyopathy that could
play prognostic and therapeutic roles.
The proinflammatory mediator HMGB1 also mediates
endotoxin lethality and plays an important role in the
pathogenesis of cardiac dysfunction and many other dis-
eases. Zhang et al. [89] showed that at least one mechan-
ism underlying HMGB1-induced cardiac dysfunction is
the increased level of intracellular ROS induced through
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HMGB1–TLR4 interaction and consequently enhanced
oxidative stress and Ca2+/calmodulin-dependent protein
kinase (CaMKII)-activated phosphorylation in ryanodine
receptor 2 (RyR2). Furthermore, HMGB1 enhances a
Ca2+ spark-mediated sarcoplasmic reticulum (SR) Ca2+
leak through the TLR4–ROS signaling pathway, which
partially depletes the SR Ca2+ content and impairs cardiac
excitation–contraction (EC) coupling. Hence, systolic
Ca2+ transients and myocyte contractility are decreased.
Inhibiting TLR4 or adding an antioxidant prevents en-
hancement of the SR Ca2+ leak, resulting in improved car-
diac EC coupling. Preventing the SR Ca2+ leak might
serve as a potential therapeutic strategy with which to
treat cardiac dysfunction associated with HMGB1
overproduction. In conclusion, circulatory DAMPs
(histone and/or HMGB1) directly injure myocytes or
damaged myocytes release these DAMPs, resulting in
myocardial dysfunction.
Management of myocardial dysfunction in septic shock
Prompt and adequate antibiotic therapy, accompanied
by surgical removal of the infectious focus, if indicated
and feasible, is the mainstay and only strictly causal line
of therapy for sepsis. The optimal treatment for myocar-
dial dysfunction includes the proper management of infec-
tion and the optimization of hemodynamic parameters.
Early control of the source and monitoring hemocultures
in conjunction with early adequate antibiotic care is im-
portant to decrease PAMPs arising from invasive microor-
ganisms (Fig. 3). Moreover, aggressive fluid replacement
guided by monitoring fluid response parameters appears
to be a rational strategy to remedy hypovolemia. While
early and sufficient fluid administration is likely to be
beneficial, excessive volume loading is harmful. The risk
of pulmonary edema formation is particularly elevated
due to increased permeability of the pulmonary microcir-
culation and LV diastolic dysfunction. Supportive therapy
encompasses early and goal-directed fluid resuscitation,
vasopressor and inotropic therapy, red blood cell
transfusion, mechanical ventilation, and renal support
when indicated. Goal-directed therapy (GDT) appears
to significantly reduce overall mortality in patients with
sepsis, especially when implemented within the first 6 h of
admission; this is called early GDT (EGDT) [90]. Early
supportive treatment is mandatory for severe sepsis and
septic shock in addition to causal therapy; this is called
Surviving Sepsis Campaign bundles [91]. Therefore, stabil-
izing arterial pressure as soon as possible is very important
to re-establish organ perfusion pressure, which helps
maintain blood flow to tissues and reduces the release of
DAMP in patients with septic shock (Fig. 3). Norepineph-
rine is the vasopressor of choice when a patient is unre-
sponsive to fluids. However, these efforts do not normalize



















Fig. 3 Management of myocardial dysfunction in septic shock. Prompt and adequate antibiotic therapy, accompanied by surgical removal of the
infectious focus if indicated and feasible, is important to decrease PAMPs arising from invasive microorganisms. Early goal-directed therapy (EGDT),
including fluid resuscitation, vasopressor and inotropic therapy, and red blood cell transfusion, is important to re-establish organ perfusion pressure,
which helps maintain blood flow to tissues and reduces the release of damage-associated molecular patterns (DAMPs) in patients with septic shock.
Sepsis bundle is a selected set of elements of care distilled from Surviving Sepsis Campaign guidelines. PAMPs pathogen-associated molecular patterns,
PRRs pattern recognition receptors, SIRS systemic inflammatory response syndrome
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indicating a high probability that sepsis-induced myo-
cardial dysfunction diminishes cardiac output [92].
Patients with myocardial depression will require ino-
tropic drugs to obtain adequate tissue perfusion and
improve hemodynamics, and dobutamine is the first
choice recommended by the Surviving Sepsis Campaign
guidelines (SSCG) 2012 [93]. After optimization of volume
status, cardiac output can be increased by inotropes.
While early administration of catecholamines might be
necessary to reverse shock and restore adequate organ
perfusion, prolonged administration, particularly at un-
necessarily high doses, might be harmful and exacerbate
myocardial damage. Furthermore, myocardial depression
causes a poor response to β-adrenergics in patients with
septic shock. Myocardial β-adrenergic receptor density is
decreased in rats with sepsis [94, 95], and stimulatory G-
proteins are decreased in rabbits with endotoxemia [96],
whereas inhibitory G-proteins are increased in both non-
survivors of septic shock and in experimental animals with
sepsis [97, 98]. These changes, namely down-regulation of
the β-adrenergic response, result in decreased adenylate
cyclase activity and reduced levels of cyclic adenosine
monophosphate. Barraud et al. [99] showed that the
calcium-sensitizing drug levosimendan at least partially
restored cardiac contraction, relaxation, and filling with-
out altering vascular properties in a model of human sep-
sis with myocardial dysfunction, whereas the cyclic
adenosine monophosphate (cAMP)-dependent inotropes
milrinone (a phosphodiesterase 3 inhibitor) and dobuta-
mine did not. By contrast, both milrinone and dobutamine
corrected systolic impairment but did not restore diastolic
function. These findings confirmed that levosimendan
works as a strategic therapy targeting cardiac abnor-
malities in patients with sepsis. However, no definitive
studies have supported levosimendan as the optimal
choice of medication for patients presenting with
myocardial dysfunction due to sepsis, and its application
to treat such patients has not been authorized in a few
countries (including Japan).
Beta-blockers can prevent ischemia, decrease oxygen
demand (by reducing cardiac output up to 20 % without
worsening oxygen utilization or increasing lactate levels),
and decrease TNF-α production [100], allowing for better
preservation of cardiac function. Beta-blocking agents
could be beneficial because evidence suggests that
beta adrenergic stress is a major factor in the pathogen-
esis of sepsis-induced myocardial dysfunction [101]. The
ultrashort-acting beta-blocker landiolol is associated with
a significant reduction in serum levels of the inflammatory
mediator HMGB1 and histological lung damage [102].
Gore and Wolfe [103] showed that esmolol, another
ultrashort-acting beta-blocker, could reduce the risk of
myocardial ischemia without the systemic consequences
of hypoperfusion in patients with sepsis. Schmittinger and
coworkers [104] found that combining milrinone with the
enteral beta-blocker metoprolol maintained the cardiac
index with a lower heart rate and a higher stroke volume
index. Information about this issue in humans is scarce
and controversy surrounds the notion that to administer a
negative inotropic drug to a patient with sepsis-induced
myocardial dysfunction is potentially deleterious. Recom-
binant thrombomodulin (rTM) has been approved for
treating DIC in Japan, and it is currently undergoing a
phase III clinical trial in the USA. In addition to its anti-
coagulant role, rTM play a role in regulating DAMPs-
mediated inflammation, in part through the neutralization
of extracellular histones and HMGB1 [87, 105]. However,
further detailed study is required to evaluate the effective-
ness of rTM against histones or HMGB1-induced myocar-
dial dysfunction in septic shock.
Conclusions
The pathophysiology of sepsis-induced myocardial dys-
function has not yet been defined, and topics range from
patho-mechanisms to treatment. In reality, only support
treatment is available for patients with sepsis and no
specific drug can reverse the associated sepsis-induced
myocardial dysfunction. Therefore, prompt appropriate
antibiotic therapy accompanied by surgical removal of
the infectious focus is very important for decreasing
PAMPs, and supportive treatment comprising early ag-
gressive fluid resuscitation with concurrent vasopressors
and inotropic therapy is mandatory for septic shock. The
SSCG recommend these bundle therapies, through
which the initial hyper-activation of the innate immune
system characterized by sepsis might be controlled. New
approaches to the treatment of sepsis and a deeper
understanding of its mechanisms should help improve
the prognosis of patients with myocardial dysfunction
in the near future.
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